We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Amgen Inc | NASDAQ:AMGN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -11.54 | -3.71% | 299.755 | 299.70 | 299.89 | 312.73 | 297.52 | 310.88 | 2,655,120 | 18:52:04 |
From May 2019 to May 2024
By Nicholas Hatcher
Amgen Inc. (AMGN) said its Phase 3 trial studying its Evolocumab cholesterol drug met its primary endpoint of the reduction in LDL-C, or "bad" cholesterol.
The Thousand Oaks, Calif., pharmaceutical company said its TESLA trial of Evolocumab "in patients with homozygous familial hypercholesterolemia, a rare and serious disease" demonstrated positive top-line results.
Safety was generally balanced across treatment groups, the company said, and the most common adverse events were upper respiratory tract infection, influenza, gastroenteritis and nasopharyngitis.
Evolocumab is an investigational fully human monoclonal antibody that inhibits a protein that reduces the liver's ability to remove bad cholesterol from the blood.
Write to Nicholas Hatcher at nicholas.hatcher@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Amgen Chart |
1 Month Amgen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
